Quanterix Corporation (QTRX) Stock
Key stats
- Market cap
- $131.95M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$1.54
- Volume
- Loading
- 52-week high
- $8.77
- 52-week low
- $2.15
Source: third-party data provider, as of October 23, 2026
Compare with QTRX
Recent news

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
QTRX

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QTRX

Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
QTRX

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
QTRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.96
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.01
- MACD histogram
- -0.07
- SMA 50
- $2.98
- Price below SMA 50
- EMA 50
- $3.12
- Price below EMA 50
- SMA 200
- $4.00
- Price below SMA 200
- EMA 200
- $4.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.27 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
QTRX

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QTRX

Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
QTRX

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
QTRX

Quanterix Q2 Earnings Call Highlights
Quanterix Q2 Earnings Call Highlights
QTRX

Quanterix Names Jim Gute Chief Commercial Officer
Quanterix Names Jim Gute Chief Commercial Officer
QTRX

Quanterix Releases Financial Results for the Second Quarter of 2026
Quanterix Releases Financial Results for the Second Quarter of 2026
QTRX

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
QTRX

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
QTRX

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QTRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Everett V. Cunningham | President, CEO & Director | 1966 |
| Mr. William P. Donnelly | Executive Chair | 1962 |
| Dr. David R. Walt Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1953 |
| Mr. Jason Faessler | CFO & Treasurer | — |
| Mr. Anthony Catalano | Chief Operating Officer | — |
| Dr. Michael Miller Ph.D. | Chief Technology & Products Officer | 1964 |
| Joshua Young | Head of Investor Relations | — |
| Mr. Daniel S. Char J.D. | Chief Legal Officer & Corporate Secretary | 1961 |
| Ms. Erica Bell | Chief People Officer | 1973 |
| Mr. Naren Bhat | Chief Strategy Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 23, 2026
Technical indicators
- RSI 14
- 41.96
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.01
- MACD histogram
- -0.07
- SMA 50
- $2.98
- Price below SMA 50
- EMA 50
- $3.12
- Price below EMA 50
- SMA 200
- $4.00
- Price below SMA 200
- EMA 200
- $4.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $3.00
- Average
- $3.25
- High
- $3.50
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.2 | -25.3 | +10.0 | |||||||||
| 2022 | -28.2 | +4.9 | -7.6 | -27.2 | -27.8 | -1.7 | -4.8 | -38.4 | +19.7 | +5.6 | +19.0 | +2.9 |
| 2023 | +9.9 | -23.3 | +6.8 | +13.3 | +55.4 | +12.0 | +13.8 | +7.5 | +0.6 | -18.7 | +11.8 | +7.7 |
| 2024 | -18.6 | +3.6 | -12.7 | -32.2 | -3.2 | -14.8 | +16.4 | -7.3 | +6.0 | +5.8 | -8.2 | -15.2 |
| 2025 | -14.6 | -14.0 | -8.2 | -13.6 | -9.9 | +26.7 | -11.2 | -22.4 | +20.9 | -3.6 | +37.2 | -8.8 |
| 2026 | -1.4 | +0.8 | -44.4 | -10.1 | -10.0 | +23.4 | -19.8 | -28.0 | +47.8 | -18.2 |



